At a glance
ClinicalIndex Comparison RecordN/ACompleted· 112 enrolled
Drug / intervention
AXA1957 +2 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 16-Week, Single-Blind Randomized, Placebo- Controlled Food Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
In Brief
A clinical study evaluating AXA1957, AXA1125, and 1 other intervention for NAFLD. Completed, enrolled 112 participants across 18 sites.
Detailed Summary
This is a randomized, single blind study to determine whether AXA1125 or AXA1957, novel compositions of amino acids, are safe and well tolerated. Subjects have non-alcoholic fatty liver disease (NAFLD) and the study will also examine liver biology using blood tests and magnetic resonance imaging (MRI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNAFLD
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartDec 2018
First PostedAug 2019
Primary CompletionMar 2020
Study CompletionSep 2020
TodayJul 2026
First PostedAug 29, 2019
Enrollment StartDec 3, 2018
Primary CompletionMar 31, 2020
Study CompletionSep 3, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.8 years ago
Interventions
AXA1957dietary
Amino acids, food study
AXA1125dietary
Amino acids, food study
Placebodietary
Amino acids, food study